Guifu Wu
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study.
Journal: Drug design, development and therapy
Published: August 05, 2025
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.
Journal: Signal transduction and targeted therapy
Published: April 26, 2025
Central vs. Peripheral Venous Oxaliplatin Administration and Chemotherapy-Induced Peripheral Neuropathy Severity.
Journal: Pain management nursing : official journal of the American Society of Pain Management Nurses
Published: October 11, 2024
Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
Journal: British journal of cancer
Published: July 16, 2024
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
Journal: Investigational new drugs
Published: April 15, 2024
FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.
Journal: Frontiers in oncology
Published: January 24, 2024
Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma.
Journal: Frontiers in oncology
Published: December 17, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026